
Raffaele Colombo/LinkedIn
Aug 8, 2025, 12:00
Raffaele Colombo: Is There a Synergistic Effect Between Enfortumab Vedotin and Pembrolizumab?
Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, posted on X:
“Is there a synergistic effect between enfortumab vedotin (EV) and pembrolizumab (P) for untreated advanced urothelial carcinoma in clinical setting?
This analysis suggests no! EV+P seems to follow a an independent drug action model with no evidence of synergy.”
Title: Assessment of synergistic vs. independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinoma
Authors: Ryan D. Chow, Ronac Mamtani
More posts featuring Raffaele Colombo.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 8, 2025, 11:47
Aug 8, 2025, 11:33